{"id":519839,"date":"2021-07-29T08:04:26","date_gmt":"2021-07-29T12:04:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/"},"modified":"2021-07-29T08:04:26","modified_gmt":"2021-07-29T12:04:26","slug":"augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/","title":{"rendered":"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387"},"content":{"rendered":"
\n

\n Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays<\/strong>\n <\/p>\n

\n Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern<\/strong>\n <\/p>\n

\n Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387<\/strong>\n <\/p>\n

\n Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results<\/strong>\n <\/p>\n

MENLO PARK, Calif.\u00a0and\u00a0AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) — Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and\u00a0TFF Pharmaceuticals, Inc.\u00a0(NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro<\/em> data indicating that their lead anti-COVID-19 monoclonal antibody (\u201cmAb\u201d) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.<\/p>\n

Recent data indicates that the Delta variant, which was recently declared a \u201cVariant of Concern\u201d by the World Health Organization, is more transmissible than the wild-type SARS-CoV-2 strain and other variants. The Delta variant now accounts for 83% of new cases in the U.S., according to recent CDC data. Demonstration that AUG-3387 effectively neutralizes the Delta variant in vitro<\/em> is an encouraging step towards developing the therapy to slow and prevent ongoing spread of COVID-19.<\/p>\n

\u201cWe are very excited about these new data, which reinforce our view that AUG-3387 could represent an important new class of biologic-based treatment modalities that can effectively target the emerging and potentially more pathogenic variants of the SARS-CoV-2 virus,\u201d stated Dr.\u00a0Christopher Emig, Chief Executive Officer of Augmenta Bioworks. \u201cAs global health officials look for innovative solutions to help curb human-to human spread of coronaviruses, we expect the treatment landscape for COVID-19 to evolve so that scalable, biologic-based therapies can play a more prominent role in efficiently combating viral transmission, particularly with respect to new, more infectious COVID-19 variants.\u201d<\/p>\n

Glenn Mattes, Chief Executive Officer of\u00a0TFF Pharmaceuticals, added, \u201cThe rapid progress we are making with respect to generating positive in vitro<\/em> data speaks to the enthusiasm both TFF and Augmenta have for evaluating the potential of AUG-3387 to combat all prevalent forms of the SARS-CoV-2 virus.\u00a0Our collaboration also demonstrates how combining two highly innovative and complementary technology platforms can accelerate rapid advancements in drug development to address severe threats to global public health. We look forward to reporting further updates on the AUG-3387 program later this year.\u201d<\/p>\n

Augmenta\u00a0and\u00a0TFF Pharmaceuticals\u00a0plan to develop AUG-3387 as an inhaled therapy for the treatment of COVID-19 disease in two types of individuals: (1) those already infected with SARS-CoV-2 who are at a high risk for severe disease but who have not yet been hospitalized, and (2) for the prevention of SARS-CoV-2 infection for individuals who are at a high risk for severe disease.<\/p>\n

The companies have selected a final formulation of AUG-3387 that will be used to complete\u00a0in vivo<\/em>\u00a0preclinical efficacy studies in the coming weeks and will proceed with toxicology studies by the end of 2021. Ongoing formulation development studies are expected to demonstrate that a sufficient dose of AUG-3387 to achieve a neutralizing concentration in the lungs can be delivered via already approved commercial dry powder inhaler devices.<\/p>\n

In prior in vitro<\/em> preclinical testing, AUG-3387 effectively neutralized SARS-CoV-2 and demonstrated activity against other major COVID variants of concern, including the previously identified\u00a0Alpha variant\u00a0(B.1.1.7), Beta variant (B.1.351),\u00a0Gamma variant\u00a0(P.1) and\u00a0Kappa variant\u00a0(B.1.617.1). The additional positive neutralization data against the delta variant reflects TFF and Augmenta\u2019s ongoing commitment to monitor activity of AUG-3387 against emerging SARS-CoV-2 variants, and to develop a therapy that is as effective as possible against currently dominant strains.<\/p>\n

TFF Pharmaceuticals and Augmenta also announced that Catalent Biologics has been selected to conduct cell line development utilizing their proprietary GPEx\u00ae<\/sup> platform and to lead drug substance manufacturing and scale-up efforts for AUG-3387 as the program advances through clinical development. Commenting on the agreement, Dr. Emig continued, \u201cWith AUG-3387 quickly emerging as a promising treatment against COVID-19, including for currently dominant variants, the selection of the CDMO is a critical decision along our development pathway. As one of the leading global providers of advanced biologics, Catalent brings exceptionally strong expertise in manufacturing of monoclonal antibodies. Augmenta and TFF look forward to working with them as the AUG-3387 program continues to advance.\u201d<\/p>\n

\n About the Development Agreement Between Augmenta Bioworks and TFF Pharmaceuticals <\/strong>\n <\/p>\n

In\u00a0November 2020, Augmenta Bioworks and TFF Pharmaceuticals announced establishment of a worldwide\u00a0Joint Development\u00a0and Collaboration Agreement to develop novel commercial products incorporating Augmenta\u2019s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics. TFF Pharmaceuticals\u00a0also obtained the option to develop two additional Augmenta mAbs for indications other than COVID-19. These antibodies are expected to be developed utilizing TFF Pharmaceuticals\u2019 Thin Film Freezing technology to manufacture dry powder formulations for inhalation delivery directly to the lungs of patients. The Agreement also includes the development of formulations suitable for parenteral administration, where the Thin Film Freezing dry powder formulations can be reconstituted, potentially mitigating the impacts of cold-chain storage and handling.\u00a0<\/p>\n

\n About Augmenta Bioworks<\/strong>\n <\/p>\n

Augmenta Bioworks is a venture-backed biotechnology company leveraging immune profiling technologies to enable breakthroughs in medicine. Through its DeepGridTM<\/sup> and SingleCyteR<\/sup> Technologies, Augmenta profiles human immunity at unprecedented scale and speed, shrinking new drug discovery timelines from years to days. The company’s platform utilizes the latest software, automation, microfluidics, high throughput DNA sequencing, and scalable computational analysis to identify immune receptors and their antigen specificity. The results are therapeutics derived from natural human immunity. The company works through partnerships in antibody discovery (infectious disease), cell therapy development (oncology), and other advanced research (auto-immunity).<\/p>\n

\n About\u00a0TFF Pharmaceuticals\u00a0<\/strong>\n <\/p>\n

TFF Pharmaceuticals, Inc.\u00a0is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics.\u00a0TFF Pharmaceuticals\u00a0has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the U.S. and internationally. To learn more about\u00a0TFF Pharmaceuticals\u00a0and its product candidates, visit the Company\u2019s website at\u00a0https:\/\/tffpharma.com<\/a>.<\/p>\n

\n SAFE HARBOR\u00a0<\/strong>\n <\/p>\n

This press release contains forward-looking statements regarding\u00a0TFF Pharmaceuticals, Inc., including the benefits of the Company\u2019s TFF platform, its Joint Development\u00a0and Collaboration Agreement with Augmenta Bioworks, TFF\u2019s and Augmenta\u2019s potential joint development of AUG-3387 to combat the SARS-CoV-2 virus and its variants and the parties\u2019 potential joint development of two additional Augmenta mAbs for indications other than COVID-19. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that results obtained in dry powder formulation and in vitro testing of AUG-3387 and any other Augmenta mAbs may not be indicative of results obtained in future preclinical or clinical trials; (ii) the risk that TFF Pharmaceuticals\u2019 dry powder formulation of AUG-3387 and any other Augmenta mAbs may not advance through the preclinical development and clinical trial process on a timely basis, or at all; (iii) the risk that the results of such trials will not warrant submission for approval from the\u00a0United States Food and Drug Administration\u00a0or equivalent foreign regulatory agencies; (iv) the risk that\u00a0TFF Pharmaceuticals\u00a0and Augmenta may not be able to successfully conclude clinical testing or obtain pre-market approval of their dry powder versions of AUG-3387 or any other Augmenta mAbs, (v) the fact that no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi)\u00a0TFF Pharmaceuticals\u00a0has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, and (vi) those other risks disclosed in the section \u201cRisk Factors\u201d included in the TFF Pharmaceuticals\u2019 2020 Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0March 10, 2021.\u00a0TFF Pharmaceuticals\u00a0cautions readers not to place undue reliance on any forward-looking statements.\u00a0TFF Pharmaceuticals\u00a0does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.<\/p>\n

\n Company Contacts:<\/strong>\n <\/p>\n

Glenn Mattes
President and CEO
TFF Pharmaceuticals, Inc
gmattes@tffpharma.com<\/a>
737-802-1973<\/p>\n

Kirk Coleman
Chief Financial Officer
TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com<\/a>
817-989-6358<\/p>\n

Christopher Emig, Ph.D.
President and CEO
Augmenta Bioworks, Inc
chris@augbio.com<\/a>
650-731-2842<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Gwendolyn Schanker
LifeSci Communications
(269) 921-3607
gschanker@lifescicomms.com<\/u><\/a><\/p>\n

Source: TFF Pharmaceuticals, Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387 Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results MENLO PARK, Calif.\u00a0and\u00a0AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) — Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and\u00a0TFF Pharmaceuticals, Inc.\u00a0(NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (\u201cmAb\u201d) therapy, AUG-3387, binds to and neutralizes … <\/p>\n

Continue reading “Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519839","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAugmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387 Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results MENLO PARK, Calif.\u00a0and\u00a0AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) — Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and\u00a0TFF Pharmaceuticals, Inc.\u00a0(NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (\u201cmAb\u201d) therapy, AUG-3387, binds to and neutralizes … Continue reading "Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T12:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387\",\"datePublished\":\"2021-07-29T12:04:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/\"},\"wordCount\":1500,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/\",\"name\":\"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==\",\"datePublished\":\"2021-07-29T12:04:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/","og_locale":"en_US","og_type":"article","og_title":"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387 - Market Newsdesk","og_description":"Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387 Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results MENLO PARK, Calif.\u00a0and\u00a0AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) — Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and\u00a0TFF Pharmaceuticals, Inc.\u00a0(NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (\u201cmAb\u201d) therapy, AUG-3387, binds to and neutralizes … Continue reading \"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T12:04:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387","datePublished":"2021-07-29T12:04:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/"},"wordCount":1500,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/","name":"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==","datePublished":"2021-07-29T12:04:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODg1MiM0MzIwNzAxIzUwMDA4MDQ2Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/augmenta-bioworks-and-tff-pharmaceuticals-announce-positive-in-vitro-data-demonstrating-binding-and-neutralization-of-the-sars-cov-2-delta-variant-by-lead-anti-covid-19-antibody-aug-3387\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519839"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519839\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}